Results 171 to 180 of about 27,201 (202)

Lapatinib

Reactions Weekly, 2020
openaire   +2 more sources

Lapatinib as a Chemotherapeutic Drug

Recent Patents on Anti-Cancer Drug Discovery, 2009
Human epidermal growth factor receptor (HER) signaling is frequently associated with the development and progression of several types of cancers. Both the MAPK and the PI3K/Akt pathways have been implicated as effectors of HER signaling by promoting anti-apoptotic and pro-proliferative effects in cancer cells. As a result, many anti-HER drugs have been
openaire   +2 more sources

Lapatinib

Reactions Weekly, 2013
  +4 more sources

Lapatinib

Reactions Weekly, 2011
openaire   +2 more sources

Lapatinib

Reactions Weekly, 2015
  +4 more sources

Lapatinib

Reactions Weekly, 2017
openaire   +2 more sources

Phase II study on lapatinib in advanced EGFR-positive chordoma†

Annals of Oncology, 2013
Luigi Mariani, Silvia Stacchiotti, Elena Tamborini   +2 more
exaly  

Lapatinib

Drugs of the Future, 2005
null Boyd, B., null Bozzo, J., null Castaner, J., null Bayes, M.   +3 more
openaire   +1 more source

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

Annals of Oncology, 2011
Antonello Vidiri, Stefania Gori, Giulio Metro   +2 more
exaly  

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

Annals of Oncology, 2013
Yoshiya Horimoto, Raoul Charles Coombes, Jacqui A Shaw   +2 more
exaly